GGrantIndex
← Leaderboards

Benjamin D Medoff

Massachusetts General Hospital

$9,952,016
Attributed
$14,453,554
Total exposure
11
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,453,554 · 11

By mechanism

R01$6,795,597 · 4
U01$4,814,561 · 2
T32$1,168,188 · 1
R21$915,750 · 2
K08$648,710 · 1
F32$110,748 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungLung DiseasesPathogenesisCellsMediatingPathway InteractionsSignal TransductionImmuneMolecularImmune ResponseLung InjuryAsthmaNew Therapeutic TargetT-LymphocyteIn VivoMouse ModelT-Cell ActivationInfectionComplexTissuesMorbidity - Disease RateInflammationGenesGene Expression

Grant awards (34)

Mapping Airway Epithelial Cell-Immune Cell Interactions in Lung Health and Disease$781,312
U01 · FY2025 · HL · contact PI
Targeting durotaxis in lung injury and fibrosis$582,439
R01 · FY2025 · HL · contact PI
A CRISPR based organoid screen for mediators of epithelial-myeloid interactions$453,750
R21 · FY2025 · AI · contact PI
Mapping Airway Epithelial Cell-Immune Cell Interactions in Lung Health and Disease$798,062
U01 · FY2024 · HL · contact PI
Targeting durotaxis in lung injury and fibrosis$570,791
R01 · FY2024 · HL · contact PI
Trained Immunity in the Airway Mucosa Differentiates Asthma from Allergy Alone$210,000
R21 · FY2024 · AI · contact PI
Targeting durotaxis in lung injury and fibrosis$580,759
R01 · FY2023 · HL · contact PI
Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosis$420,000
R01 · FY2023 · HL · contact PI
Trained Immunity in the Airway Mucosa Differentiates Asthma from Allergy Alone$252,000
R21 · FY2023 · AI · contact PI
Targeting durotaxis in lung injury and fibrosis$559,550
R01 · FY2022 · HL · contact PI
Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosis$420,000
R01 · FY2022 · HL · contact PI
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary Fibrosis$673,211
R01 · FY2019 · HL · contact PI
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary Fibrosis$673,211
R01 · FY2018 · HL · contact PI
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary Fibrosis$673,211
R01 · FY2017 · HL
HIV and COPD:Immune mediated mechanisms$655,958
U01 · FY2017 · HL · contact PI
HIV and COPD:Immune mediated mechanisms$655,958
U01 · FY2016 · HL · contact PI
HIV and COPD:Immune mediated mechanisms$655,958
U01 · FY2015 · HL · contact PI
HIV and COPD:Immune mediated mechanisms$642,841
U01 · FY2014 · HL · contact PI
HIV and COPD:Immune mediated mechanisms$624,472
U01 · FY2013 · HL · contact PI
Role of Carma1 in Inflammatory Lung Disease$411,700
R01 · FY2011 · HL
Training Grant in Lung Cell and Molecular Biology$372,839
T32 · FY2011 · HL · contact PI
Role of Carma1 in Inflammatory Lung Disease$411,700
R01 · FY2010 · HL
Training Grant in Lung Cell and Molecular Biology$399,249
T32 · FY2010 · HL · contact PI
Role of Carma1 in Inflammatory Lung Disease$410,475
R01 · FY2009 · HL
Training Grant in Lung Cell and Molecular Biology$396,100
T32 · FY2009 · HL · contact PI
Role of Carma1 in Inflammatory Lung Disease$408,550
R01 · FY2008 · HL
Chemokines in lung transplantation$129,870
K08 · FY2007 · HL · contact PI
Chemokines in lung transplation$129,870
K08 · FY2006 · HL · contact PI
Chemokines in lung transplation$129,870
K08 · FY2005 · HL
Chemokines in lung transplation$129,870
K08 · FY2004 · HL
Chemokines in lung transplantation$129,230
K08 · FY2003 · HL
Role of the Leukotriene B4 Receptors in Asthma$6,984
F32 · FY2003 · AI
Role of the Leukotriene B4 Receptors in Asthma$54,352
F32 · FY2002 · AI
Role of the Leukotriene B4 Receptors in Asthma$49,412
F32 · FY2001 · AI